SUN YAT-SEN MEMORIAL HOSPITAL,SUN YAT-SEN UNIVERSITY

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The Efficacy of Radiomics to Predict Tumor Microenvironment Markers and Comprehensive Therapy for Bladder Cancer

Completed

Conditions: Immunotherapy
Bladder Cancer
Radiomics

First Posted Date: 2024-04-24

Last Posted Date: 2024-04-24

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 1200

Registration Number: NCT06381895

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

Clinical Trial of Microneedle Radiofrequency Combined With Oral Isotretinoin in Moderate to Severe Acne

Not Applicable

Recruiting

Conditions: Moderate to Severe Acne Vulgaris

Interventions: Other: Oral isotretinoin combined with microneedle radiofrequency therapy
Drug: Oral isotretinoin

First Posted Date: 2024-04-23

Last Posted Date: 2024-04-23

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 100

Registration Number: NCT06378983

Locations: 🇨🇳
Department of Dermatology and Venereology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University., Guangzhou, China

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Phase 2

Not yet recruiting

Conditions: HNSCC
Head and Neck Cancer
Head Cancer Neck
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Tislelizumab
Drug: Polymeric Micellar Paclitaxel
Procedure: Surgical Resection of Primary +/- Neck Dissection
Radiation: Post-operative radiation therapy

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 85

Registration Number: NCT06366945

10-year Retrospective Study of Oral and Maxillofacial Squamous Cell Carcinoma

Completed

Conditions: Radiomic
MRI
HNSCC
AI

Interventions: Diagnostic Test: The Resnet50 deep learning (DL) model

First Posted Date: 2024-04-16

Last Posted Date: 2024-04-16

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 319

Registration Number: NCT06366906

Locations: 🇨🇳
Sun yat-sen memorial hospital, Guangzhou, Guangdong, China
🇨🇳
Sun yat-sun memorial hospital, Guangzhou, Guangdong, China

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3

Not yet recruiting

Conditions: Bladder Cancer

Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine
Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib

First Posted Date: 2024-04-15

Last Posted Date: 2025-02-21

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 210

Registration Number: NCT06364904

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

and more 5 locations

Sintilimab Plus FOLFIRI as Salvage Therapy for Patients With Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Unresectable/Metastatic Gastric Cancer

Interventions: Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 40

Registration Number: NCT06365008

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China

Phase Ib/II Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Tislelizumab combined with two predefined dose groups of palbociclib
Drug: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.

First Posted Date: 2024-04-15

Last Posted Date: 2024-04-15

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 36

Registration Number: NCT06364956

Locations: 🇨🇳
Xiangya Hospital, Central South University, Changsha, Hunan, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China

and more 5 locations

Exploring the Effectiveness and Factors Affecting the Collection of Single Nucleated Cells From Different Volunteers

Not yet recruiting

Conditions: Observational Study

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 80

Registration Number: NCT06361602

De-Escalation Postoperative Radiotherapy for Oral Squamous Cell Carcinoma With pCR/MPR.

Phase 2

Recruiting

Conditions: De-escalated Radiotherapy; Head and Neck Cancer

Interventions: Radiation: Continuous, hyperfractionated, accelerated radiotherapy(CHART)

First Posted Date: 2024-04-09

Last Posted Date: 2024-05-21

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 103

Registration Number: NCT06353685

Locations: 🇨🇳
Sun Yat-sen Memorial hospital, Sun Yat-sen University, Guangzhou, China

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Interventions: Drug: Adebrelimab
Drug: Apatinib
Drug: Tegafur

First Posted Date: 2024-04-01

Last Posted Date: 2024-04-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 32

Registration Number: NCT06339619

Locations: 🇨🇳
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy